Floatz logo

f16il2

Metastatic Melanoma

Philogen S.p.A.unclassifiedPhase 1/2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
73/ 100

Competitive context

104 Active assets in the Metastatic Melanoma cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 2BBB
DACARBAZINE
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Therapeutic Autologous Lymphocytes
Fred Hutchinson Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

f16il2 is also rated in:

acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
42 / 100
View asset →
neoplasmDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →